Carbidopa, Levodopa And Entacapone Tablet, Film Coated
Product Images NDC 46708-798

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Carbidopa, Levodopa And Entacapone (NDC 46708-798). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carbilevoent-12-5-50-200mg (Carbilevoent 12 5 50 200mg)

This text provides information about the dosage and storage instructions for Carbidopa levodopa tablets with Entacapone. It includes details such as not crushing or chewing the tablets, storing them at a controlled room temperature, and ensuring they are kept out of the reach of children. It also warns against combining tablets to increase the strength due to the risk of Entacapone overdose. The tablets come in a child-resistant package and are manufactured by Alembic Pharmaceuticals Limited in India.*

FDA Label Image

Carbilevoent-18-75-75-200mg (Carbilevoent 18 75 75 200mg)

This text provides dosage instructions for Carbidopa Levodopa and Entacapone tablets. The tablets should be swallowed whole and not crushed, split, or chewed. It also includes storage information, indicating that the tablets should be stored at 25°C (77°F) and dispensed in a tight container. The tablets contain Carbidopa USP 18.75 mg, Levodopa USP 75 mg, and Entacapone USP 200 mg. The manufacturer is Alembic Pharmaceuticals Limited from Gujarat, India. Additionally, the package is child-resistant, and the text includes manufacturing license information.*

FDA Label Image

Carbilevoent-25-100-200mg (Carbilevoent 25 100 200mg)

Not Available.*

FDA Label Image

Carbilevoent-31-25-125-200mg (Carbilevoent 31 25 125 200mg)

This text provides important information about the dosage and administration of Carbidopa, Levodopa and Entacapone Tablets. It specifies not to crush, split, or chew the tablets but to swallow them whole. The storage conditions, manufacturing details, and precautions such as keeping the medication out of reach of children are also mentioned. Additionally, it warns against combining tablets to avoid entacapone overdose. The text also includes details about the tablet composition and a prescription requirement.*

FDA Label Image

Carbilevoent-37-5-150-200 (Carbilevoent 37 5 150 200)

Dosage: Swallow whole. Do not crush, split, or chew Carbidopa Levodopa tablets. Each film-coated tablet contains Carbidopa USP 37.5mg, Levodopa USP 150 mg, and Entacapone USP 200 mg. Store at 25°C (77°F) and keep out of reach of children. Manufacturer: Alembic Pharmaceuticals Limited. Avoid combining tablets to achieve a higher strength due to the risk of Entacapone overdose. Package is child-resistant. Follow package insert instructions (NDC 46708-799-31).*

FDA Label Image

Carbilevoent-50-200-200mg (Carbilevoent 50 200 200mg)

Dosage: See package insert for detailed instructions regarding Carbidopa, Levodopa, and Entacapone Tablets. Swallow whole; do not crush. Store between 15°C to 30°C (59°F to 86°F). Each film-coated tablet contains Carbidopa USP 50 mg, Levodopa USP 200 mg, and Entacapone USP 200 mg. Keep out of reach of children and dispense in a tight container. Do not combine tablets to create a higher strength tablet to avoid the risk of Entacapone overdose. Manufactured by Alembic Pharmaceuticals Limited in Gujarat, India.*

FDA Label Image

Carbilevoenta-carbidopa.jpg (Carbilevoenta Carbidopa)

FDA Label Image

Carbilevoenta-entacapone.jpg (Carbilevoenta Entacapone)

FDA Label Image

Carbilevoenta-levodopa.jpg (Carbilevoenta Levodopa)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.